BRIEF-Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies

Reuters

16 Jan

BRIEF-Silexion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies

Jan 15 (Reuters) - Silexion Therapeutics SLXN.O:

SILEXION THERAPEUTICS ANNOUNCES ADDITIONAL PROMISING PRECLINICAL DATA FOR SIL-204, DEMONSTRATING IMPRESSIVE SYNERGY WITH FIRST-LINE PANCREATIC CANCER CHEMOTHERAPIES
SILEXION THERAPEUTICS CORP - ANNOUNCES SYNERGISTIC EFFICACY OF SIL-204 IN PANCREATIC CANCER
SILEXION THERAPEUTICS CORP - COMBINATION OF SIL-204 AND CHEMOTHERAPY REDUCES CANCER CELL CONFLUENCE
SILEXION THERAPEUTICS CORP - TO INITIATE PRECLINICAL STUDIES FOR SIL-204 IN COLORECTAL CANCER

Source text: ID:nGNX5kXZ0q

Further company coverage: SLXN.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503672079"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503672079\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503672079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-16 05:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503672079","market":"us","top_or_hot":-1,"title":"BRIEF-Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Silexion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies</title></head><body><p><span>Jan 15 (Reuters)</span><span> - </span>Silexion Therapeutics <span>SLXN.O</span>:</p><ul><li><p>SILEXION THERAPEUTICS ANNOUNCES ADDITIONAL PROMISING PRECLINICAL DATA FOR SIL-204, DEMONSTRATING IMPRESSIVE SYNERGY WITH FIRST-LINE PANCREATIC CANCER CHEMOTHERAPIES</p></li><li><p>SILEXION THERAPEUTICS CORP - ANNOUNCES SYNERGISTIC EFFICACY OF SIL-204 IN PANCREATIC CANCER</p></li><li><p>SILEXION THERAPEUTICS CORP - COMBINATION OF SIL-204 AND CHEMOTHERAPY REDUCES CANCER CELL CONFLUENCE</p></li><li><p>SILEXION THERAPEUTICS CORP - TO INITIATE PRECLINICAL STUDIES FOR SIL-204 IN COLORECTAL CANCER</p></li></ul><p>Source text: <span>ID:nGNX5kXZ0q</span></p><p>Further company coverage: <span>SLXN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-16 05:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Silexion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer Chemotherapies</title></head><body><p><span>Jan 15 (Reuters)</span><span> - </span>Silexion Therapeutics <span>SLXN.O</span>:</p><ul><li><p>SILEXION THERAPEUTICS ANNOUNCES ADDITIONAL PROMISING PRECLINICAL DATA FOR SIL-204, DEMONSTRATING IMPRESSIVE SYNERGY WITH FIRST-LINE PANCREATIC CANCER CHEMOTHERAPIES</p></li><li><p>SILEXION THERAPEUTICS CORP - ANNOUNCES SYNERGISTIC EFFICACY OF SIL-204 IN PANCREATIC CANCER</p></li><li><p>SILEXION THERAPEUTICS CORP - COMBINATION OF SIL-204 AND CHEMOTHERAPY REDUCES CANCER CELL CONFLUENCE</p></li><li><p>SILEXION THERAPEUTICS CORP - TO INITIATE PRECLINICAL STUDIES FOR SIL-204 IN COLORECTAL CANCER</p></li></ul><p>Source text: <span>ID:nGNX5kXZ0q</span></p><p>Further company coverage: <span>SLXN.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLXN","symbol_name":"Silexion Therapeutics Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250115:nTUABB5RDK:1","article_id":"2503672079","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503672079","pubTimestamp":1736975016,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer ChemotherapiesJan 15 (Reuters) - Silexion Th","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"SLXN":"Silexion Therapeutics Corp"},"translate_title":"简介-Silexion Therapeutics宣布SIL-204的更多有希望的临床前数据，展示了与一线胰腺癌化疗令人印象深刻的协同作用","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLXN":0.9},"content_text":"BRIEF-Silexion Therapeutics Announces Additional Promising Preclinical Data For SIL-204, Demonstrating Impressive Synergy With First-Line Pancreatic Cancer ChemotherapiesJan 15 (Reuters) - Silexion Therapeutics SLXN.O:SILEXION THERAPEUTICS ANNOUNCES ADDITIONAL PROMISING PRECLINICAL DATA FOR SIL-204, DEMONSTRATING IMPRESSIVE SYNERGY WITH FIRST-LINE PANCREATIC CANCER CHEMOTHERAPIESSILEXION THERAPEUTICS CORP - ANNOUNCES SYNERGISTIC EFFICACY OF SIL-204 IN PANCREATIC CANCERSILEXION THERAPEUTICS CORP - COMBINATION OF SIL-204 AND CHEMOTHERAPY REDUCES CANCER CELL CONFLUENCESILEXION THERAPEUTICS CORP - TO INITIATE PRECLINICAL STUDIES FOR SIL-204 IN COLORECTAL CANCERSource text: ID:nGNX5kXZ0qFurther company coverage: SLXN.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1}}}